An Italian single-center randomized phase II clinical study (NCT04113863) is presently investigating preoperative activity of ATRA in HR+/HER2- early breast cancer in combination with non-steroidal aromatase inhibitor anastrozole. This evidence concerns the gene CYP19A1 and breast carcinoma.